Organogenesis (ORGO) Competitors $4.35 +0.30 (+7.41%) Closing price 07/3/2025 03:40 PM EasternExtended Trading$4.20 -0.15 (-3.33%) As of 07/3/2025 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ORGO vs. ADPT, IMCR, SPRY, EWTX, SDGR, BHVN, ETNB, ANIP, JANX, and EVOShould you be buying Organogenesis stock or one of its competitors? The main competitors of Organogenesis include Adaptive Biotechnologies (ADPT), Immunocore (IMCR), ARS Pharmaceuticals (SPRY), Edgewise Therapeutics (EWTX), Schrodinger (SDGR), Biohaven (BHVN), 89BIO (ETNB), ANI Pharmaceuticals (ANIP), Janux Therapeutics (JANX), and Evotec (EVO). These companies are all part of the "pharmaceutical products" industry. Organogenesis vs. Its Competitors Adaptive Biotechnologies Immunocore ARS Pharmaceuticals Edgewise Therapeutics Schrodinger Biohaven 89BIO ANI Pharmaceuticals Janux Therapeutics Evotec Adaptive Biotechnologies (NASDAQ:ADPT) and Organogenesis (NASDAQ:ORGO) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends. Does the media prefer ADPT or ORGO? In the previous week, Adaptive Biotechnologies had 3 more articles in the media than Organogenesis. MarketBeat recorded 5 mentions for Adaptive Biotechnologies and 2 mentions for Organogenesis. Adaptive Biotechnologies' average media sentiment score of 0.46 beat Organogenesis' score of 0.00 indicating that Adaptive Biotechnologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adaptive Biotechnologies 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Organogenesis 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk and volatility, ADPT or ORGO? Adaptive Biotechnologies has a beta of 1.83, suggesting that its stock price is 83% more volatile than the S&P 500. Comparatively, Organogenesis has a beta of 1.7, suggesting that its stock price is 70% more volatile than the S&P 500. Do analysts recommend ADPT or ORGO? Adaptive Biotechnologies presently has a consensus price target of $10.57, suggesting a potential downside of 11.73%. Organogenesis has a consensus price target of $6.00, suggesting a potential upside of 37.93%. Given Organogenesis' higher probable upside, analysts clearly believe Organogenesis is more favorable than Adaptive Biotechnologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adaptive Biotechnologies 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86Organogenesis 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is ADPT or ORGO more profitable? Organogenesis has a net margin of -3.46% compared to Adaptive Biotechnologies' net margin of -74.84%. Organogenesis' return on equity of -4.00% beat Adaptive Biotechnologies' return on equity.Company Net Margins Return on Equity Return on Assets Adaptive Biotechnologies-74.84% -62.79% -24.55% Organogenesis -3.46%-4.00%-2.26% Which has better earnings and valuation, ADPT or ORGO? Organogenesis has higher revenue and earnings than Adaptive Biotechnologies. Organogenesis is trading at a lower price-to-earnings ratio than Adaptive Biotechnologies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdaptive Biotechnologies$178.96M10.17-$159.49M-$0.96-12.48Organogenesis$482.04M1.14$860K-$0.17-25.59 Do insiders and institutionals have more ownership in ADPT or ORGO? 99.2% of Adaptive Biotechnologies shares are held by institutional investors. Comparatively, 49.6% of Organogenesis shares are held by institutional investors. 6.4% of Adaptive Biotechnologies shares are held by company insiders. Comparatively, 33.0% of Organogenesis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. SummaryAdaptive Biotechnologies and Organogenesis tied by winning 8 of the 16 factors compared between the two stocks. Get Organogenesis News Delivered to You Automatically Sign up to receive the latest news and ratings for ORGO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ORGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORGO vs. The Competition Export to ExcelMetricOrganogenesisMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$539.13M$2.43B$5.53B$9.05BDividend YieldN/A1.78%5.24%4.03%P/E Ratio-25.598.9827.5220.22Price / Sales1.14682.84421.02118.64Price / Cash20.37158.5936.8958.07Price / Book2.084.588.045.67Net Income$860K$31.34M$3.18B$249.13M7 Day Performance18.53%3.25%2.90%3.28%1 Month Performance51.04%7.08%3.70%5.55%1 Year Performance56.47%0.17%36.15%21.12% Organogenesis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORGOOrganogenesis4.0835 of 5 stars$4.35+7.4%$6.00+37.9%+55.9%$539.13M$482.04M-25.59950News CoverageADPTAdaptive Biotechnologies3.3343 of 5 stars$10.56+1.7%$10.57+0.1%+253.3%$1.58B$178.96M-11.00790News CoverageGap UpIMCRImmunocore2.3758 of 5 stars$31.12-0.7%$58.89+89.2%-8.4%$1.57B$310.20M-72.37320SPRYARS Pharmaceuticals3.2498 of 5 stars$16.57+4.9%$31.00+87.1%+81.4%$1.55B$89.15M-103.5690Insider TradeEWTXEdgewise Therapeutics2.4951 of 5 stars$14.18-0.8%$39.78+180.5%-29.1%$1.50BN/A-9.1560News CoverageAnalyst RevisionGap UpSDGRSchrodinger2.7999 of 5 stars$20.35-0.5%$32.80+61.2%+4.3%$1.50B$207.54M-7.74790Analyst ForecastBHVNBiohaven3.4144 of 5 stars$14.44-0.2%$58.46+305.0%-56.7%$1.48BN/A-1.54239ETNB89BIO1.9373 of 5 stars$10.00-0.8%$26.43+164.3%+35.6%$1.47BN/A-2.9640ANIPANI Pharmaceuticals3.7095 of 5 stars$66.03+0.7%$80.13+21.3%+7.4%$1.42B$614.38M-51.99600JANXJanux Therapeutics1.848 of 5 stars$22.88-3.1%$95.25+316.3%-36.3%$1.40B$10.59M0.0030EVOEvotec1.7225 of 5 stars$3.81+1.3%$5.93+55.7%-18.5%$1.34B$862.40M0.004,827News Coverage Related Companies and Tools Related Companies Adaptive Biotechnologies Alternatives Immunocore Alternatives ARS Pharmaceuticals Alternatives Edgewise Therapeutics Alternatives Schrodinger Alternatives Biohaven Alternatives 89BIO Alternatives ANI Pharmaceuticals Alternatives Janux Therapeutics Alternatives Evotec Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ORGO) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredThe mainstream media is wrong about AI — againThe mainstream media got it wrong … yet again. AI has recently turned the tech world on its head. And th...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Organogenesis Please log in to your account or sign up in order to add this asset to your watchlist. Share Organogenesis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ORGO Stock Alerts